血友病成本效果建模研究的系统综述

数据集获取（Figshare）

• 源站标题：Systematic review of cost-effectiveness modelling studies for haemophilia
• DOI：10.6084/m9.figshare.28057331.v1
• 发布日期：2024-12-18
• 文件数：2 个
• 文件总体积：300.22 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Systematic_review_of_cost-effectiveness_modelling_studies_for_haemophilia/28057331

命令行下载

curl -L -o "ijme_a_2444157_sm7764.xlsx" "https://ndownloader.figshare.com/files/51284777"
curl -L -o "ijme_a_2444157_sm7763.docx" "https://ndownloader.figshare.com/files/51284780"

文件清单

• ijme_a_2444157_sm7764.xlsx（187.26 KB）
• ijme_a_2444157_sm7763.docx（112.95 KB）

文件总体积 300.22 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Haemophilia is a rare genetic disease that hinders blood clotting. We aimed to review model-based cost-effectiveness analyses (CEAs) of haemophilia treatments, describe the sources of clinical evidence used by these CEAs, summarize the reported cost-effectiveness of different treatment strategies, and assess the quality and risk of bias.
We conducted a systematic literature review of model-based CEAs of haemophilia treatments by searching databases, the Tufts Medical Center CEA registry, and grey literature. We summarized and qualitatively synthesized the approaches and results of the included CEAs, without a meta-analysis due the diversity of the studies.
32 eligible studies were performed in 12 countries and reported 53 pairwise comparisons. Most studies analysed patients with haemophilia A rather than haemophilia B. Comparisons of prophylactic versus on-demand treatment indicated that prophylaxis may not be cost-effective, but there was no clear consensus. Emicizumab was generally cost-effective compared with clotting factor treatments and was always dominant for patients with inhibitors. Immune tolerance induction following a Malmö protocol was found to be cost-effective compared to bypassing agents, while there was no consensus for the other protocols. Gene therapies as well as treatment with extended half-life coagulation factors were always cost-effective over their comparators. Studies were highly heterogenous regarding their time horizons, model structures, the inclusion of bleeding-related mortality and quality-of-life impacts. This heterogeneity limited the comparability of the studies. 19 of the 32 included studies received industry funding, which may have biased their results.
It was not possible to perform a quantitative synthesis of the results due to the heterogeneity of the underlying studies.
Differences in results between previous CEAs may have been driven by heterogeneity in modelling approaches, clinical input data, and potential funding biases. A more consistent evidence base and modelling approach would enhance the comparability between CEAs.
Haemophilia is a rare genetic disease that hinders blood clotting. Patients with haemophilia

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.28057331.v1（source: https://tandf.figshare.com/articles/dataset/Systematic_review_of_cost-effectiveness_modelling_studies_for_haemophilia/28057331）。